Enanta Pharmaceuticals (ENTA) Net Margin (2016 - 2025)
Historic Net Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 122.9%.
- Enanta Pharmaceuticals' Net Margin rose 731100.0% to 122.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 125.19%, marking a year-over-year increase of 461000.0%. This contributed to the annual value of 125.19% for FY2025, which is 461000.0% up from last year.
- Per Enanta Pharmaceuticals' latest filing, its Net Margin stood at 122.9% for Q3 2025, which was up 731100.0% from 99.68% recorded in Q2 2025.
- Enanta Pharmaceuticals' 5-year Net Margin high stood at 99.68% for Q2 2025, and its period low was 211.62% during Q1 2023.
- Over the past 5 years, Enanta Pharmaceuticals' median Net Margin value was 148.46% (recorded in 2023), while the average stood at 150.61%.
- Per our database at Business Quant, Enanta Pharmaceuticals' Net Margin crashed by -1583900bps in 2021 and then surged by 807000bps in 2024.
- Enanta Pharmaceuticals' Net Margin (Quarter) stood at 108.92% in 2021, then decreased by -13bps to 122.9% in 2022, then crashed by -51bps to 185.56% in 2023, then rose by 29bps to 131.43% in 2024, then increased by 6bps to 122.9% in 2025.
- Its Net Margin stands at 122.9% for Q3 2025, versus 99.68% for Q2 2025 and 151.71% for Q1 2025.